摘要
目的研究BUT-6010对肿瘤的抑制作用。方法体外抗肿瘤实验:选取9种人源肿瘤细胞株,并将其分为BUT-6010组、顺铂阳性对照组、细胞对照组和培养基空白对照组,MTS法测定抑制率和IC50值;体内抗肿瘤实验:实验分为BUT-6010 10 mg/kg组、BUT-6010 20 mg/kg组、BUT-6010 30 mg/kg组、顺铂阳性对照组(2.5 mg/kg)和模型组。通过对S180荷瘤小鼠瘤重的研究,观察BUT-6010的体内抗肿瘤作用。结果 BUT-6010对9种人癌细胞株的IC50均小于顺铂。顺铂(2.5 mg/kg)的抑瘤率达51.8%(P<0.05),BUT-6010(30 mg/kg)抑瘤率为52.8%(P<0.05)。结论 BUT-6010(30 mg/kg)的安全性与有效性同顺铂(2.5 mg/kg)相当。
Objective To study the acute toxicities and anti-tumor activity of BUT-6010. Methods Anti-tumor experiment in vitro was that： nine human cancer cell lines were divided into BUT-6010 group, Cisplatin positive control group, cell control group and culture medium blank group. The inhibition rate and IC50 were studied by MTS assay; anti-tumor experi- ment in vivo was that： the study was divided into BUT-6010 of 10 mg/kg group, BUT-6010 of 20 mg/kg group, BUT-6010 of 30 mg/kg group, Cisplatin positive control group （2.5 mg/kg） and model group. The anti-tumor activity of BUT-6010 in vivo was observed by studying the S180 tumor-bearing mice. Results The IC50 of BUT-6010 in nine human cancer cell lines was lower than that of Cisplatin. The inhibition rate of Cisplatin （2.5 mg/kg） was 51.8% （P 〈 0.05）, the inhibition rate of BUT-6010 （30 mg/kg） was 52.8% （P 〈 0.05）. Conclusion The safety and efficacy of BUT-6010 （30 mg/kg） is the same as Cisplatin （2.5 mg/kg）.
出处
《中国医药导报》
CAS
2012年第25期16-17,25,共3页
China Medical Herald
基金
浙江省科技计划项目(项目名称:新一代铂类广谱抗癌药BUT-6001的开发
项目编号:2008C14081)
作者简介
王燕萍（1979．9-），女，江苏无锡人，药理学硕士研究生，药理室副主任，中级职称，参与了靶向抗癌药盐酸埃克替尼的药理学研究；研究方向：抗肿瘤新药研究。
[通讯作者]谭芬来（1963-），博士。
